M Grimm1, F Wenz2. 1. Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68135, Mannheim, Deutschland. mario.grimm@umm.de. 2. Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68135, Mannheim, Deutschland.
Abstract
BACKGROUND: Radiation therapy is an established cornerstone in the treatment of prostate cancer. Significant advances in the techniques and therapeutic concepts have been made in recent decades. OBJECTIVES: The objective of this article is to provide an overview of current standards of care and recent technical and conceptional developments. CONCLUSIONS: Three-dimensional conformal radiotherapy has long been the standard of care for percutaneous radiotherapy. The development of intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) have increased the precision of treatment, thus, reducing side effects and allowing dose escalation. LDR (low dose rate) and HDR (high dose rate) brachytherapy alone or in combination are a treatment option in localized prostate cancer with a distinct side effect profile. The roles of proton therapy and stereotactic radiotherapy should be further investigated in prospective trials.
BACKGROUND: Radiation therapy is an established cornerstone in the treatment of prostate cancer. Significant advances in the techniques and therapeutic concepts have been made in recent decades. OBJECTIVES: The objective of this article is to provide an overview of current standards of care and recent technical and conceptional developments. CONCLUSIONS: Three-dimensional conformal radiotherapy has long been the standard of care for percutaneous radiotherapy. The development of intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) have increased the precision of treatment, thus, reducing side effects and allowing dose escalation. LDR (low dose rate) and HDR (high dose rate) brachytherapy alone or in combination are a treatment option in localized prostate cancer with a distinct side effect profile. The roles of proton therapy and stereotactic radiotherapy should be further investigated in prospective trials.
Authors: Amr M Emara; Eliot Chadwick; Jenny P Nobes; Ather Mohamed Abdelbaky; Robert W Laing; Stephen E M Langley Journal: BJU Int Date: 2011-08-19 Impact factor: 5.588
Authors: Anna Wilkins; Helen Mossop; Isabel Syndikus; Vincent Khoo; David Bloomfield; Chris Parker; John Logue; Christopher Scrase; Helen Patterson; Alison Birtle; John Staffurth; Zafar Malik; Miguel Panades; Chinnamani Eswar; John Graham; Martin Russell; Peter Kirkbride; Joe M O'Sullivan; Annie Gao; Clare Cruickshank; Clare Griffin; David Dearnaley; Emma Hall Journal: Lancet Oncol Date: 2015-10-28 Impact factor: 41.316